Back to Results

Volitionrx Ltd (VNRX)

VolitionRx Ltd is a common stock listing on the NYSE for VolitionRx Limited, a multinational healthcare company focused on epigenetics-based diagnostics. The company develops blood tests intended to detect and monitor multiple cancers as well as diseases linked to NETosis across the United States, Europe, and Asia. Its product and development portfolio includes Nu.Q Vet for cancer screening in animals, Nu.Q Nets for identifying NETosis-related conditions such as sepsis, Nu.Q Discover for nucleosome profiling, Nu.Q Cancer for supporting cancer treatment response and disease monitoring, and Capture-PCR and Capture-Seq for isolating circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-VNRX
$0.39
47.1% Upside
Undervalued
$13.62 5,079.5% Upside
Not available
Bargain
Weak
0.0%
November 12, 2026
1.5x
3.738 M
11.004 M
82.7%
88.2%
-55.9
75.0%
Valuation • Fair Value

Volitionrx Ltd (NYSE-VNRX) Fair Value by Valuation Model

Review the available estimates for Volitionrx Ltd (NYSE-VNRX), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.39

Estimated upside of 47.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.39

Comparable-company valuation reference.

Analyst Price Target

$13.62 5,079.5% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Volitionrx Ltd (NYSE-VNRX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Volitionrx Ltd (NYSE-VNRX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

2.458 M

Current operating scale indicator.

Revenue Forecast

2.565 M

Forward revenue estimate.

EBITDA

-18.573 M

Current operating profitability reference.

EBITDA Forecast

-12 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Volitionrx Ltd (NYSE-VNRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Volitionrx Ltd (NYSE-VNRX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-5.59

No elevated caution signal from this screen.

Altman Z-Score

-55.9

Lower score that deserves closer risk review.

FCF / Net Income

75.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Volitionrx Ltd (NYSE-VNRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Volitionrx Ltd (NYSE-VNRX)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

51

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Volitionrx Ltd (NYSE-VNRX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Volitionrx Ltd (NYSE-VNRX) Stock Forecast & Technical Outlook

Review Volitionrx Ltd (NYSE-VNRX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Volitionrx Ltd (NYSE-VNRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Volitionrx Ltd (NYSE-VNRX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Volitionrx Ltd (NYSE-VNRX) has a Strong Buy consensus, with 3 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 1
Sell 0
FAQ • Fast Investor Answers

Volitionrx Ltd (NYSE-VNRX) Stock FAQ

Data-supported answers about Volitionrx Ltd (NYSE-VNRX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.39
Estimated upside 47.1%
Valuation Rating
Undervalued
Estimated upside of 47.1%
Analyst Target
$13.62 5,079.5% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Volitionrx Ltd (NYSE-VNRX) is $0.39. This implies an estimated upside of 47.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 47.1% versus the current market price.

The available analyst price target for Volitionrx Ltd (NYSE-VNRX) is $13.62 5,079.5% Upside.

The current financial health read for Volitionrx Ltd (NYSE-VNRX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Volitionrx Ltd (NYSE-VNRX) is November 12, 2026.

The latest available data indicates no current dividend yield for Volitionrx Ltd (NYSE-VNRX).

The current market capitalization listed for Volitionrx Ltd is 3.738 M.

The current enterprise value listed for Volitionrx Ltd is 11.004 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Volitionrx Ltd is NYSE-VNRX, and the stock is listed on NYSE.

Volitionrx Ltd (NYSE-VNRX) is listed on NYSE.

The current debt-to-total-capital ratio listed for Volitionrx Ltd is 82.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Volitionrx Ltd is 88.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NYSE

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 179.4 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 142 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 116.1 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 65.099 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 51.173 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.847 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 44.185 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 41.084 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 33.785 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 31.756 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.674 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 29.933 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.452 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 20.357 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 17.926 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.107 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.581 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 12.242 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.566 B